Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Ascendis Pharma A/S ASND

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis... see more

NDAQ:ASND - Post Discussion

Ascendis Pharma A/S > ASND Price Target Alert: $200.00. Issued by Goldman Sachs
View:
Post by whytestocks on Sep 16, 2024 3:16pm

ASND Price Target Alert: $200.00. Issued by Goldman Sachs

Breaking News: $ASND ASND Price Target Alert: $200.00. Issued by Goldman Sachs2024-09-16 15:00:05 ET Paul Choi from Goldman Sachs issued a price target of $200.00 for ASND on 2024-09-16 12:06:00. The adjusted price target was set to $200.00. At the time of the announcement, ASND was trading at $142.26. The overall price target consensus is at $174...ASND - ASND Price Target Alert: $200.00. Issued by Goldman Sachs
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities